摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

溴吡马嗪 | 145-54-0

中文名称
溴吡马嗪
中文别名
——
英文名称
Propyromazine bromide
英文别名
2-(1-methylpyrrolidin-1-ium-1-yl)-1-phenothiazin-10-ylpropan-1-one;bromide
溴吡马嗪化学式
CAS
145-54-0
化学式
C20H23BrN2OS
mdl
——
分子量
419.4
InChiKey
OANVFVBYPNXRLD-UHFFFAOYSA-M
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    228-229°

计算性质

  • 辛醇/水分配系数(LogP):
    1.45
  • 重原子数:
    25
  • 可旋转键数:
    2
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.35
  • 拓扑面积:
    45.6
  • 氢给体数:
    0
  • 氢受体数:
    3

文献信息

  • NOVEL BRONCHODILATING DIAZAHETEROARYLS
    申请人:Johansson Martin
    公开号:US20120040942A1
    公开(公告)日:2012-02-16
    The invention relates to novel compounds having the general formula (I), and which compounds are useful to treat a disorder or disease characterized by bronchoconstriction, e.g. COPD and asthma.
    这项发明涉及具有通式(I)的新化合物,这些化合物可用于治疗由支气管痉挛引起的疾病或疾病,例如慢性阻塞性肺疾病(COPD)和哮喘。
  • [EN] NOVEL BRONCHODILATING DIAZAHETEROARYLS<br/>[FR] NOUVEAUX DIAZAHÉTÉROARYLES BRONCHODILATATEURS
    申请人:RESPIRATORIUS AB
    公开号:WO2010097410A1
    公开(公告)日:2010-09-02
    The invention relates to novel compounds having the general formula (I), and which compounds are useful to treat a disorder or disease characterized by bronchoconstriction, e.g. COPD and asthma.
    这项发明涉及具有通式(I)的新化合物,这些化合物可用于治疗由支气管痉挛引起的疾病或疾病,例如慢性阻塞性肺疾病(COPD)和哮喘。
  • Technology for the Preparation of Microparticles
    申请人:Malakhov Michael
    公开号:US20090098207A1
    公开(公告)日:2009-04-16
    Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.
    微球是通过将溶液中的大分子或小分子与抗溶剂和对离子接触,并冷却溶液而制备的。这些微球可用于制备具有明确定义尺寸的药物、营养保健品、化妆品等产品。
  • Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders
    申请人:Fraser Oliver Matthew
    公开号:US20050113421A1
    公开(公告)日:2005-05-26
    A method is provided for using Cav2.2 subunit calcium channel modulators, particularly thiazolidinone, oxazolidinone, and imidazolone derivatives, to treat non-inflammatory gastrointestinal tract disorders.
    提供了一种方法,用于使用Cav2.2亚单位通道调节剂,特别是噻唑啉酮、噁唑啉酮和咪唑啉酮衍生物,来治疗非炎症性胃肠道疾病。
  • [EN] BRONCHORELAXING COMPOUNDS<br/>[FR] COMPOSES BRONCHO-RELACHANTS
    申请人:RESPIRATORIUS AB
    公开号:WO2005070887A1
    公开(公告)日:2005-08-04
    A compound of the general formula (I) including its pharmaceutically acceptable acid addition salts formula (I) wherein A is CHR9, wherein R9 is H, C1-C6 alkyl;n is 1-3; B is CHR10, wherein R10 is H, C1-C6 alkyl; m is 1 or 2; D is O or S; E is CR11R12 or NR13, wherein R11 and R12 are, independent of each other, H or C1-C6 alkyl, R13 is H or C1-C6 alkyl; F is C1-C18 alkyl or R4-R7 cycloalkyl, which may be mono- or di-unsaturated and/or substituted, is useful in treating and preventing pulmonary disease characterized by bronchoconstriction; also disclosed is a pharmaceutical composition comprising the compound of formula (I), a pharmaceutical carrier and, optionally, an anti-asthmatic, a method for its manufacture, and a method for treating or preventing such disease.
    通式(I)的化合物及其药学上可接受的酸加合盐,其中A为CHR9,其中R9为H,C1-C6烷基;n为1-3;B为CHR10,其中R10为H,C1-C6烷基;m为1或2;D为O或S;E为CR11R12或NR13,其中R11和R12独立地为H或C1-C6烷基,R13为H或C1-C6烷基;F为C1-C18烷基或R4-R7环烷基,可以是单烯或双烯和/或取代的,用于治疗和预防以支气管收缩为特征的肺部疾病;还公开了包含通式(I)的药物组合物、药物载体和可选的抗哮喘药、其制造方法以及治疗或预防该疾病的方法。
查看更多